Trials, 2021 Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases.
Stephen I. Walimbwa +5 more
doaj +1 more source
International Journal of Infectious Diseases, 2023 Objectives: Georgia introduced remdesivir for the treatment of COVID-19 in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among inpatients with COVID-19.
Revaz Metchurtchlishvili +6 more
doaj +1 more source
A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]
, 2019 Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y. +2 more
core +1 more source
Clinical Outcomes of Remdesivir in COVID-19 Patients with Acute Kidney Injury or Chronic Kidney Disease: A Randomized Clinical Trial [PDF]
, 2023 Background: remdesivir is an RNA polymerase inhibitor approved to treat moderate to severe Coronavirus Disease 2019 (COVID-19); however, it has not yet been authenticated to apply to patients with acute kidney injury (AKI) or chronic kidney disease (CKD).
Alirezaei, Toktam +3 more
core +2 more sources
Is remdesivir the therapeutic answer for COVID-19: a review of current knowledge [PDF]
, 2020 As the world races to find the solution to the COVID-19 pandemic, an investigational agent which has triggered worldwide interest is remdesivir. Though failing clinical trials for treatment of Ebola virus disease, remdesivir has shown efficacy in ...
Ahsan, Marya, Mallick, Ayaz Khurram
core +2 more sources
Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry [PDF]
, 2022 Aim To evaluate the association of remdesivir use and the survival of hospitalized patients with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the medical re - cords of 5959 COVID-19 patients admitted to our ...
Babić, Paško +13 more
core +2 more sources
Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study [PDF]
, 2022 Background: to date the optimal antiviral treatment against severe coronavirus disease 2019 (COVID-19) has not been proven; remdesivir is a promising drug with in vitro activity against several virus, but in COVID-19 the clinical results are currently ...
Bianchi, Bianca +8 more
core +1 more source
Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
Frontiers in Microbiology, 2020 Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy.
Wei Ye +16 more
doaj +1 more source
Pharmacology Research & Perspectives, 2021 Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption device are applied in the treatment of severe COVID‐19. The CytoSorb® adsorber consists of porous polymer beads that adsorb a broad range of molecules, including ...
Paul Biever +7 more
doaj +1 more source
Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report
Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2022 Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported.
Sidhi Laksono Purwowiyoto +1 more
doaj +1 more source